Pharmicell Co Ltd
KRX:005690
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (39.7), the stock would be worth ₩28 488.78 (60% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 24.8 | ₩17 770 |
0%
|
| 3-Year Average | 39.7 | ₩28 488.78 |
+60%
|
| 5-Year Average | 42.6 | ₩30 525.11 |
+72%
|
| Industry Average | 31.4 | ₩22 474.1 |
+26%
|
| Country Average | 10 | ₩7 153.42 |
-60%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
Pharmicell Co Ltd
KRX:005690
|
1.1T KRW | 24.8 | 26.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 21.6 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 23 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 17.7 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 28.3 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 11.9 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 111.9 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 14.5 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.8 |
| Median | 10 |
| 70th Percentile | 18.7 |
| Max | 2 215 163.4 |
Other Multiples
Pharmicell Co Ltd
Glance View
Pharmicell Co., Ltd. is engaged in the development of stem cell based pharmaceuticals and technologies. The company is headquartered in Seoul, Seoul and currently employs 127 full-time employees. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. The company also provides steam cell storage services, and mesenchymal stem cells (MSCs) used for research areas and others. In addition, the Company engages in the fashion business, which provides women’s and men’s apparels under the brand names of Religion and Day. On March 31, 2013, the Company merged with its wholly owned subsidiary, mainly engaged in the manufacture and sale of medicines.
